Statement on FDA's Approval of XENAZINE(R) for the Treatment of Chorea Associated With Huntington's Disease
Posted on: Friday, 15 August 2008, 18:00 CDT
NEW YORK, Aug. 15 /PRNewswire/ -- The Hereditary Disease Foundation (HDF) is extremely pleased the U.S. Food and Drug Administration has approved Xenazine, or tetrabenazine, for the treatment of chorea associated with Huntington's disease.
"Chorea is a major cause of disability and death in patients with Huntington's disease. Chorea is not just a mere inconvenience; it can prevent Huntington's disease patients from walking, talking, working, watching television and almost every aspect of one's life. We are ecstatic that, through the approval of Xenazine, patients and families will have the option to take the only drug developed specifically for treating the movements of Huntington's disease," said Nancy Wexler, Ph.D., Higgins Professor of Neuropsychology in the departments of neurology and psychiatry at Columbia University and president of the Hereditary Disease Foundation.
"While we are still hopeful we can some day find a cure, the approval of Xenazine is a breakthrough for the Huntington's disease community," said Dr. Wexler.
The approval of Xenazine marks the first and only FDA-approved treatment for any symptom of Huntington's disease.
Hereditary Disease Foundation
CONTACT: Nancy Wexler, Ph.D., of Hereditary Disease Foundation,+1-212-543-5667
Source: PRNewswire
Related Articles
- Cardinal Health Foundation Awards $1 Million to Fund Patient Safety Initiatives
- Arterial Disease of The Leg Commonly Overlooked in Patients with Heart Disease
- Kidney Disease Increases the Risk of Stroke in Patients With the Most Common Type of Heart Arrhythmia, According to Kaiser Permanente Study
- Hereditary Angioedema Drug is Approved
- Dentalxchange.Com Launches Patient Financing Program Designed to Increase Patient Approvals
- National Kidney Foundation Introduces Plan to Track Patients in National Screening Program
- Judge Rules That Florida Disease Management Program Serving 8,000 HIV/AIDS Patients Should Be Re-Bid, Says AIDS Healthcare Foundation
- Heart Disease and Lung Cancer Won't Wait, But Patients May Have to Wait for Life-Saving Care
- Collaborative Disease Management: Leveraging MCO Data to Improve Patient Outcomes
- Impact of a Negative Evaluation for Underlying Coronary Artery Disease on One-Year Resource Utilization for Patients Admitted With Potential Acute Coronary Syndromes
 |
 |
User Comments (0)
RSS Feeds